OGEN vs REGN · rev $37.7K vs P/E 14, rev $14.34B
Oragenics Inc (OGEN) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Oragenics Inc (OGEN) is a biotechnology company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported OGEN revenue for 2023-12-31 was $37.7K. Net income was -$20.7M. Revenue was down 71.4% from 2022-12-31 to 2023-12-31. OGEN currently screens at market cap $2.7M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
OGEN currently screens at market cap $2.7M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the OGEN and REGN stock pages for the full models.
Not investment advice.